What is the primary driver of Abbott's significant sales increase in the reported periods?

The primary driver of Abbott's significant sales increase in the second quarter and first six months of 2018 was the acquisition of Alere Inc., which closed in October 2017. This acquisition greatly strengthened the Diagnostics segment. Additionally, strong organic growth across all business segments, particularly in Diagnostics and Established Pharmaceuticals, contributed to the overall sales performance.

How has the company's debt position changed, and what is its approach to managing debt?

Abbott has actively managed its debt position. During the first six months of 2018, the company repaid $2.8 billion of a term loan and $1.15 billion under its revolving credit agreement. Further, it redeemed $947 million of 5.125% Notes due 2019 and $1.055 billion of 2.35% Notes due 2019, followed by another $1.3 billion redemption of the 2.35% Notes due 2019. This has led to a significant reduction in long-term debt. Abbott's strategy appears focused on debt reduction and maintaining an investment-grade credit rating.

What impact did the adoption of new accounting standards have on the financial statements?

Abbott adopted new accounting standards during the reporting period. Notably, the adoption of ASU 2014-09 (Revenue from Contracts with Customers) as of January 1, 2018, resulted in a $23 million increase to Retained Earnings, with no significant impact on financial statement line items. The adoption of ASU 2017-07 (Improving the Presentation of Net Periodic Pension Cost) in Q1 2018 led to a retrospective reclassification of approximately $80 million of pension and post-retirement benefit costs from 'Operating earnings' to 'Other (income) expense, net' for the first six months of 2017, affecting the comparability of operating results between periods.

What is the outlook for Research and Development (R&D) spending?

Abbott's R&D expenses increased in both the second quarter and the first six months of 2018, primarily due to the inclusion of the Alere business and increased spending in other areas, particularly Cardiovascular and Neuromodulation. This suggests a continued strategic focus on innovation and product development, which is crucial for sustained growth in the healthcare industry.

ABT 10-Q Quarterly Report Q2 FY2018 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong top-line growth for the second quarter and first six months of 2018, with total net sales increasing by 17.0% and 16.8% respectively compared to the prior year. This growth was significantly boosted by the acquisition of Alere Inc. in late 2017, which solidified Abbott's position in the diagnostics market, particularly in point-of-care testing. Excluding foreign exchange impacts, net sales grew by 15.3% and 14.0% for the respective periods, demonstrating robust underlying performance across key segments including Pharmaceuticals, Nutritionals, Diagnostics, and Cardiovascular & Neuromodulation. While the company experienced a significant decrease in cash and cash equivalents due to debt repayment and dividend payments, operational cash flow remained strong. The company continues to manage its debt effectively, with substantial repayments made during the period. Investors should note the company's ongoing integration of recent acquisitions and its commitment to research and development, which is reflected in increased R&D expenses, particularly in the Cardiovascular and Neuromodulation segment. The financial statements also reflect the adoption of new accounting standards, notably the revenue recognition standard (ASU 2014-09) and changes in pension expense presentation (ASU 2017-07).

Financial Highlights

52 data points

Beta

Revenue

$7.77B

0.5% Gross Margin

Net Income

$733.00M

0.1% Net Margin

EPS (Diluted)

$0.41

Total Assets

$68.42B

Cash & Equivalents

$3.06B

Free Cash Flow

$946.00M

Financial Statements

Beta

Revenue	$7.77B
Cost of Revenue	$3.28B
Gross Profit	$3.92B
R&D Expenses	$575.00M
SG&A Expenses	$2.47B
Operating Expenses	$6.88B
Operating Income	$882.00M
Interest Expense	$210.00M
Net Income	$733.00M
EPS (Basic)	$0.42
EPS (Diluted)	$0.41
Shares Outstanding (Basic)	1.76B
Shares Outstanding (Diluted)	1.77B

Key Highlights

1Total net sales increased by 17.0% in Q2 2018 and 16.8% for the first six months of 2018, reaching $7.8 billion and $15.2 billion respectively, driven by organic growth and the Alere acquisition.
2The Diagnostics segment saw substantial growth of 47.2% in Q2 and 52.6% year-to-date, primarily due to the integration of Alere, enhancing Abbott's leadership in point-of-care testing.
3Operating earnings showed a significant improvement, growing from $386 million in Q2 2017 to $882 million in Q2 2018, and from $144 million year-to-date in 2017 to $1,490 million year-to-date in 2018.
4Despite a decrease in cash and cash equivalents from $9.4 billion to $3.1 billion, net cash from operating activities increased by $427 million to $2.35 billion for the first six months of 2018.
5The company repaid a substantial amount of debt, including a $2.8 billion term loan and $1.15 billion under its revolving credit agreement, contributing to a decrease in long-term debt from $27.2 billion to $19.8 billion.
6Research and Development expenses increased by 10.5% in Q2 and 8.4% year-to-date, reflecting ongoing investment in innovation, particularly within the Cardiovascular and Neuromodulation segment.
7Abbott adopted new accounting standards, including ASU 2014-09 for revenue recognition and ASU 2017-07 for pension expense presentation, impacting prior period comparisons and financial statement presentation.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2018

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions